Published in Alzheimers Dement on October 01, 2014
Community-based Cohort of Functional Decline in Subjective Cognitive Complaint Elderly | NCT04265482
The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events. Front Neurosci (2015) 1.02
Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron (2014) 0.93
Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement (Amst) (2015) 0.90
The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimers Dement (2015) 0.90
Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy. J Alzheimers Dis (2016) 0.85
Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimers Dement (Amst) (2015) 0.83
The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF-α, TGF-β and IFN-γ. Transl Neurodegener (2016) 0.82
Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. Alzheimers Dement (Amst) (2016) 0.82
The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment. Alzheimers Dement (Amst) (2015) 0.82
Plasma sphingolipid changes with autopsy-confirmed Lewy Body or Alzheimer's pathology. Alzheimers Dement (Amst) (2016) 0.81
Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement (2016) 0.80
Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging. Ann Clin Transl Neurol (2016) 0.79
Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling. Mol Brain (2016) 0.78
Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology. J Alzheimers Dis (2015) 0.78
Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Neurotherapeutics (2016) 0.78
The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. J Prev Alzheimers Dis (2014) 0.78
Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics. Neurodegener Dis Manag (2016) 0.77
Protein signature in cerebrospinal fluid and serum of Alzheimer's disease patients: The case of apolipoprotein A-1 proteoforms. PLoS One (2017) 0.77
Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. Front Neurol (2015) 0.76
Introduction to special issue on Advances in blood-based biomarkers of Alzheimer's disease. Alzheimers Dement (Amst) (2016) 0.76
PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease. J Prev Alzheimers Dis (2016) 0.75
Study protocol: Insight 46 - a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurol (2017) 0.75
Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease. Curr Alzheimer Res (2016) 0.75
Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer's disease patients from non-demented subjects. Oncotarget (2017) 0.75
Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients. Alzheimers Res Ther (2016) 0.75
Why most published research findings are false. PLoS Med (2005) 41.68
Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov (2011) 22.33
Policy: NIH plans to enhance reproducibility. Nature (2014) 15.71
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Monetary costs of dementia in the United States. N Engl J Med (2013) 6.77
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging (1998) 5.05
Errors in laboratory medicine. Clin Chem (2002) 4.87
2013 Alzheimer's disease facts and figures. Alzheimers Dement (2013) 4.75
Mistakes in a stat laboratory: types and frequency. Clin Chem (1997) 4.08
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell (2011) 3.01
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology (2005) 2.76
HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics (2005) 2.71
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr (2009) 2.54
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther (2011) 2.51
Stability studies of twenty-four analytes in human plasma and serum. Clin Chem (2002) 2.46
A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol (2010) 2.42
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement (2013) 1.90
Transfusion medicine monitoring practices. A study of the College of American Pathologists/Centers for Disease Control and Prevention Outcomes Working Group. Arch Pathol Lab Med (1995) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid (2000) 1.75
Biomarkers in Alzheimer's disease drug development. Nat Med (2010) 1.61
Impact of blood collection devices on clinical chemistry assays. Clin Biochem (2009) 1.61
Serum and plasma proteomics. Chem Rev (2007) 1.56
A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One (2011) 1.55
Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem (2006) 1.54
Preanalytical quality improvement: in quality we trust. Clin Chem Lab Med (2013) 1.52
Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin Chem Lab Med (2008) 1.50
Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One (2011) 1.46
Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis (2014) 1.29
Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci (2009) 1.24
The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement (2013) 1.22
Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther (2009) 1.17
Antecedent biomarkers of Alzheimer's disease: the adult children study. J Geriatr Psychiatry Neurol (2005) 1.16
A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord (2011) 1.14
Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis. Clin Chem (2012) 1.11
A gene expression pattern in blood for the early detection of Alzheimer's disease. J Alzheimers Dis (2011) 1.10
Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease. Neuropsychopharmacology (2013) 1.08
Identification of a blood-based biomarker panel for classification of Alzheimer's disease. Int J Neuropsychopharmacol (2011) 1.07
Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement (2012) 1.07
Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteomics (2006) 1.01
Bio-banking in microbiology: from sample collection to epidemiology, diagnosis and research. FEMS Microbiol Rev (2005) 1.00
Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. J Alzheimers Dis (2012) 1.00
Nonspecific binding of Aβ42 to polypropylene tubes and the effect of Tween-20. Clin Chim Acta (2010) 0.99
A comparison of hemolysis rates using intravenous catheters versus venipuncture tubes for obtaining blood samples. J Emerg Nurs (1996) 0.98
Factors affecting hemolysis rates in blood samples drawn from newly placed IV sites in the emergency department. J Emerg Nurs (2005) 0.98
Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement (2014) 0.96
Influence of sample type on soluble CD40 ligand assessment in patients with acute coronary syndromes. Thromb Res (2007) 0.95
Specimen collection and handling: standardization of blood sample collection. Methods Mol Biol (2008) 0.95
Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing. J Alzheimers Dis (2012) 0.95
Protein instability following transport or storage on dry ice. Nat Methods (2013) 0.94
Specimen collection, storage, and transmission to the laboratory for hematological tests. Int J Hematol (2002) 0.94
Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice. JAMA (2009) 0.94
Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems. Alzheimers Res Ther (2013) 0.94
Scaling of hemolysis in needles and catheters. Ann Biomed Eng (1998) 0.94
Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio. Biol Psychiatry (2009) 0.93
The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma beta-amyloid isoforms using the INNO-BIA plasma Abeta forms multiplex assay. J Nutr Health Aging (2009) 0.92
Elevated serum potassium values: the role of preanalytic variables. Am J Clin Pathol (2004) 0.89
Biological and methodical challenges of blood-based proteomics in the field of neurological research. Prog Neurobiol (2012) 0.87
Mapping out biomarkers for Alzheimer disease. JAMA (2011) 0.86
Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol (2012) 0.86
Storage of whole blood: effect of temperature on the measured concentration of analytes in serum. Clin Chem (1988) 0.85
Impact of preanalytical variables on the analysis of biological fluids in proteomic studies. Proteomics Clin Appl (2007) 0.85
Immune profiling in blood identifies sTNF-R1 performing comparably well as biomarker panels for classification of Alzheimer's disease patients. J Alzheimers Dis (2013) 0.85
Evaluation and use of diagnostic tests in Alzheimer's disease. Neurobiol Aging (1998) 0.84
Laboratory sampling. Does the process affect the outcome? J Intraven Nurs (2000) 0.84
Diurnal variations in biomarkers used in cardiovascular medicine: clinical significance. Rev Esp Cardiol (2009) 0.83
Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. J Nutr Health Aging (2013) 0.83
Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes. Biomark Med (2013) 0.82
Plastic collection tubes decrease risk of employee injury. MLO Med Lab Obs (2001) 0.81
Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis. J Neurol (2012) 0.81
The clinical chemistry laboratory: current status, problems and diagnostic prospects. Anal Bioanal Chem (2005) 0.81
Using blood markers for Alzheimer disease in clinical practice? Neurology (2012) 0.79
Preanalytic conditions of the C-reactive protein are of paramount importance to use as a predictor of cardiovascular disease in clinical practice. Int J Cardiol (2012) 0.76
A risk-analysis approach to the evaluation of analytical quality. Clin Chem Lab Med (2011) 0.76
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement (2016) 1.93
The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement (2013) 1.22
Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues. J Alzheimers Dis (2014) 0.95
NIPT and Informed Consent: an Assessment of Patient Understanding of a Negative NIPT Result. J Genet Couns (2016) 0.84
Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimers Dement (Amst) (2015) 0.83
SIBLING family genes and bone mineral density: association and allele-specific expression in humans. Bone (2014) 0.81
Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. Hum Mol Genet (2016) 0.79
Genetics of alcoholism. Handb Clin Neurol (2014) 0.78
Ethanol treatment of lymphoblastoid cell lines from alcoholics and non-alcoholics causes many subtle changes in gene expression. Alcohol (2014) 0.77
A blood screening test for Alzheimer's disease. Alzheimers Dement (Amst) (2016) 0.77
Combining select neuropsychological assessment with blood-based biomarkers to detect mild Alzheimer's disease: a molecular neuropsychology approach. J Alzheimers Dis (2014) 0.77
The impact of APOE status on relationship of biomarkers of vascular risk and systemic inflammation to neuropsychiatric symptoms in Alzheimer's disease. J Alzheimers Dis (2014) 0.77
Molecular Markers of Amnestic Mild Cognitive Impairment among Mexican Americans. J Alzheimers Dis (2015) 0.76
Genome-wide linkage analyses of non-Hispanic white families identify novel loci for familial late-onset Alzheimer's disease. Alzheimers Dement (2015) 0.76
Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans. Alzheimers Dement (2016) 0.75
DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study. Lancet Neurol (2016) 0.75
Molecular markers of neuropsychological functioning and Alzheimer's disease. Alzheimers Dement (Amst) (2015) 0.75
Characteristics of Bipolar I patients grouped by externalizing disorders. J Affect Disord (2015) 0.75
Linkage analyses in Caribbean Hispanic families identify novel loci associated with familial late-onset Alzheimer's disease. Alzheimers Dement (2015) 0.75
Knowledge gaps and research recommendations for essential tremor. Parkinsonism Relat Disord (2016) 0.75
Exome Sequencing Identifies Candidate Genetic Modifiers of Syndromic and Familial Thoracic Aortic Aneurysm Severity. J Cardiovasc Transl Res (2017) 0.75
A Genome Wide Association Study of Fast Beta EEG in Families of European Ancestry. Int J Psychophysiol (2016) 0.75